Koios DS
Koios Medical, Inc. • Radiology • 11/15/2024
Device Purpose
Koios DS is an artificial intelligence and machine learning-based computer-aided diagnosis software designed to assist physicians in interpreting breast and thyroid ultrasound images. It employs automated image analysis to generate cancer risk assessments and lexicon-based descriptors, aiming to enhance diagnostic accuracy and streamline clinical workflow.
Summary
Koios Medical, Inc. has developed Koios DS, an artificial intelligence and machine learning-based computer-aided diagnosis (CADx) software. This software is designed to assist trained interpreting physicians during diagnostic ultrasound examinations of lesions or nodules suspicious for breast or thyroid cancer. Following a review, the Koios DS device was determined to be substantially equivalent to legally marketed predicate devices for its specified indications for use, allowing it to be marketed. Koios DS enables users to select regions of interest within ultrasound images for automated analysis, which generates a cancer risk assessment and applicable lexicon-based descriptors to enhance diagnostic accuracy and reduce variability. The software also functions as a multi-modality image viewer with tools for image adjustment, measurement, and structured reporting. Key enhancements include improved performance for the breast classification engine and maintained strong performance for the thyroid engine with an AI Adapter. New features like Thyroid Smart Click, Image Registration and Matching, and Optical Character Recognition further streamline the workflow.
AI Regulatory Concerns
Powered by
Jev reads the full FDA letter and returns calibrated concern probabilities per regulatory category. These are AI estimates, not regulatory advice.
Keywords
Device Metadata
Relevant Clinical Questions
- Q1. How does the AI/ML model for Koios DS handle false positives and negatives in real-world clinical settings, especially considering its CADx nature?; What specific metrics were used to assess the "improved performance" of the breast classification engine and the "strong performance" of the thyroid engine with the AI Adapter?; Can Koios DS integrate with existing PACS systems and electronic health records to provide a more seamless diagnostic workflow?; What kind of training or certification is required for physicians to effectively utilize Koios DS, particularly concerning the interpretation of its cancer risk assessments and lexicon descriptors?; How does the "Image Registration and Matching" feature contribute to diagnostic confidence, particularly in longitudinal studies of lesions?
Risk Classification
ESL AnalysisFDA Class II via 510(k) pathway; IEC 62304 Class B (software safety classification); Post-§524B but no clear network capability detected
Learn how Parasoft automates IEC 62304 compliance testing →Cybersecurity Evidence
Powered by SBOMator™Based on AI-generated device summaries, not the full FDA submission. Items not detected here may still be present in the complete submission package.
Supply Chain BOM Evidence
Based on the CycloneDX / OWASP ECMA-424 xBOM ecosystem. Detection is from the AI-generated summary.
Analysis:
• Analysis is based on the AI-generated device summary, not the full FDA submission package. Click "Analyze Full FDA PDF" below to scan the actual submission document.
• Evidence of ML-BOM detected in AI-generated device summary.
• SBOM not mentioned in AI-generated device summary. Under §524B (effective Oct 2023), cyber devices must provide a SBOM.
• Cybersecurity risk assessment not referenced in AI-generated device summary. FDA cybersecurity guidance (2023) expects this for cyber devices.
• Not detected in AI-generated device summary: SBOM, SaaSBOM, HBOM, CBOM, VDR/VEX, OBOM. These may be present in the full FDA submission.
Preparing a similar submission?
ESL takes complete ownership of your software evidence work - SBOM & CVE remediation with SBOMator™, static analysis & unit testing with Parasoft, traceability, and full IEC 62304 lifecycle support.
Assess Your Readiness →Or contact ESL directly